title: Targeted biopharmaceuticals for cancer treatment.
abstract: Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. This article reviews the biological function and application of targeted anticancer biopharmaceuticals. We first discuss the specific antigens and core pathways that are used in the development of targeted cancer therapy. The innovative monoclonal antibodies, non-antibody proteins, and small molecules targeting these antigens or pathways are then reviewed. Finally, the current challenges in anticancer biopharmaceuticals development and the potential solutions to address these challenges are discussed.
authors.affiliation: Departments of Medicine and Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Lufang
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, USA.
authors.forename: Ningning
authors.initials: N
authors.lastname: Xu
authors.affiliation: Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China; Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, USA; Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China. Electronic address: mliu@eng.ua.edu.
authors.forename: Xiaoguang Margaret
authors.initials: XM
authors.lastname: Liu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use; D015195:Drug Design; D016568:Drugs, Generic / Q000627:therapeutic use; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D011506:Proteins / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001688:Biological Products; D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic; D011506:Proteins
keywords: Anticancer biopharmaceuticals; Biosimilar; Innovative biologics; Targeted therapy